Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Tibial Fractures
Interventions: CP-533,536, Placebo, Standard of Care; Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 17 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 11
States / cities: Wichita, Kansas • Worcester, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Anaheim, California • Los Angeles, California • Orange, California + 28 more

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 23
States / cities: San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more

Conditions: Healthy Volunteer, Female, Breast
Interventions: Denosumab, Percutaneous core needle breast biopsy; Drug · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Cypress, California • Hollywood, Florida • Miami, Florida

Conditions: Opioid-Related Disorders
Interventions: oxycodone and naltrexone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Arthritis, Rheumatoid
Interventions: CP-195,543, celecoxib, Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 39
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more

Conditions: Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions: Cyclobenzaprine; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hair Thinning
Interventions: Nutrafol Supplement Capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Healthy
Interventions: ST-246, Placebo; Drug
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Covid19
Interventions: Silmitasertib, SOC; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions: Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU; Drug · Dietary Supplement
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Arrest
Interventions: Laerdal Q-CPR /technology; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more

Conditions: Obesity, Childhood
Interventions: iChoose, Family Connections; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 138
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Halobetasol Propionate Lotion 0.05%, Placebo; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: San Diego, California • Fridley, Minnesota • Austin, Texas

Conditions: Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Interventions: Nirmatrelvir, Placebo, Ritonavir; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 81
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Acute Myocardial Infarction, Moderate Renal Impairment
Interventions: CSL_112, Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, Placebo; Drug · Biological
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New Haven, Connecticut • The Woodlands, Texas

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 32
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more

Search by objective public record fields.

ACTiF- Assessment of Closed Tibial Fractures

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Effect of Denosumab on Cellular Biomarkers in the Human Breast

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Japanese Bridging Study Conducted in the United States

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

Automated Real-time Feedback on CPR Study

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

A Trial of Two Family-based Childhood Obesity Treatment Programs

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Paxlovid for Treatment of Long Covid

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer